==================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
October 1, 2003 |
|
Date of Report (Date of earliest event reported) |
|
ORAGENICS, INC. |
|
(Exact name of registrant as specified in its charter) |
|
Florida |
333-100568 |
59-3410522 |
|
(State or other jurisdiction |
(Commission |
(IRS Employer |
|
12085 Research Drive |
|
(Address of principal executive offices including zip code) |
|
(386) 418-4018 |
|
Registrant's telephone number, including area code |
|
None |
|
(Former name or former address, if changed since last report.) |
==================================================================================
ITEM 7. FINANCIAL INFORMATION AND EXHIBITS
|
Exhibit No. |
Description |
|
99.1 |
Press Release |
ITEM 9. REGULATION FD DISCLOSURE
David J. Gury, retired founding CEO and current Chairman of the Board of Nabi Biopharmaceuticals, has been appointed to the Company's Board of Directors.
- 2 -
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 1st day of October, 2003.
|
|
ORAGENICS, INC. |
|
|
|
BY: |
/s/ Paul Hassie |
|
|
|
Paul Hassie |
- 3 -